Novel amyloid beta oligomer specific binding molecule
AssigneeDegenRx B.V.
InventorsSamantha Kathleen COBB, Michael FOLEY, Augustinus Petrus Henricus SCHEEFHALS, Armand Wilbrandt Jannes Wichert TEPPER
Life of this patent
Estimating the term…
Abstract
This disclosure relates to an amyloid beta peptide (Aβ)-oligomer-specific antigen binding molecule and the use thereof as a diagnostic agent or as a therapeutic agent for the treatment or prevention of Alzheimer's Disease, Down's syndrome, mild cognitive impairment, cerebral amyloid angiopathy, vascular dementia, multi-infarct dementia, Parkinson's disease, Dementia with Lewy Bodies, Huntington's disease, Creutzfeldt-Jakob disease, cystic fibrosis, or Gaucher's disease.
Claims24
An amyloid beta peptide (Aβ)-oligomer-specific antigen binding molecule displaying the following characteristics:
- an affinity for Aβ-oligomers of less than 1 nM;
- and
- an at least 50-fold greater specificity for Aβ-oligomers than for Aβ-fibrils.
An amyloid beta peptide (Aβ)-oligomer-specific antigen binding molecule comprising an amino acid sequence comprising the structure X-CDR1-Y-CDR3-Z;
- in which:
- CDR1 comprises the amino acid sequence of amino acid residues 27-32 of SEQ ID NO:1 (QNGWSR) or an amino acid sequence having at least 50% sequence identity to the amino acid sequence of amino acid residues 27-32 of SEQ ID NO:1;
- and
- CDR3 comprises the amino acid sequence of amino acid residues 85-102 of SEQ ID NO:1 (LLNPRREEFWFSRRYPVV) or an amino acid sequence having at least 50% sequence identity to the amino acid sequence of amino acid residues 85-102 of SEQ ID NO:1.
Dependencies are inferred from the claim text.